0.00Open0.00Pre Close0 Volume0 Open Interest130.00Strike Price0.00Turnover91.57%IV-46.91%PremiumDec 20, 2024Expiry Date114.89Intrinsic Value100Multiplier27DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9960Delta0.0002Gamma2.12Leverage Ratio-0.0279Theta0.0974Rho2.11Eff Leverage0.0080Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet